To study the role of RAC1-regulated cellular processes in response to FLT3 inhibitors, we developed midostaurin-resistant AML cell lines from the FLT3-ITD homozygous and heterozygous AML cell lines MV4-11 and MOLM-13, respectively. The gene discussed is FLT3; the disease is acute myeloid leukemia.